Navigation Links
Exiqon A/S: Interim Report for the Period 1 January - 30 June 2008 (Unaudited)
Date:8/28/2008

VEDBAEK, Denmark, August 28 /PRNewswire-FirstCall/ -- Strong organic growth continued in Q2 2008 supported by new research product offerings. The development of Exiqon's first molecular diagnostic product based on miRNA profiling remains on track for year end launch.

- Revenue in Q2 2008 increased by 139% on the year-earlier period to DKK

28 million, totaling DKK 44.5 million in the first six months of 2008.

- Product sales in Q2 2008 increased by 239% on the same period last year

to DKK 26.3 million (including research product sales and diagnostic

sales) totaling DKK 40.5 million in the first six months of 2008.

Research product sales grew organically by 70% compared to Q2 2007.

- Direct contribution margin in Q2 2008 was 65% compared to 78% in the

same period last year, totaling 66% in the first six months of 2008.

Gross margin was 25% compared to 64% in the same period last year,

totaling 33% in the first six months of 2008. The gross margin was

affected by new product offerings and cost of unused capacity during the

current build-up phase.

- Total operating expenses in Q2 2008 increased by 80% on the same period

last year to DKK 48.3 million, totaling DKK 82.7 million in the first six

months of 2008. The increase in operating expenses is primarily due to

the acquisition of Oncotech Inc.

- Net loss for Q2 2008 was DKK 38.8, totaling DKK 63.5 million the first

six months of 2008. EPS amounted to DKK -1.37 in Q2 2008 and DKK -2.25 in

the first six months of 2008.

- Based on current activities, the financial guidance for 2008

is retained with revenue of DKK 140-150 million in 2008 including both

research product sales and diagnostic sales. A net loss of DKK 100-115

million is expected, for the full year 2008, including the effect of

costs of current incentive plans in the amount to DKK 6 million.

Lars Kongsbak, President and CEO says: "With financing in place to reach expected break even by 2011 and on track towards our goal of a cash flow positive life sciences business by the end of 2009, there is no doubt that Exiqon is in a sweet spot in the biotechnology market. We see a strong interest in miRNA and we are very excited about the launch of our first molecular diagnostic product based on miRNA by year end."

For full report please click on the link:

http://exiqon.com/SEEEMS/10815.asp


'/>"/>
SOURCE Exiqon A/S
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Exiqon Receives the 2008 Frost & Sullivan Growth Strategy Leadership Award
2. Exiqon Appoints Cynthia French as Chief Scientific Officer and Erik Holmlin as Chief Commercial Officer
3. Exiqon: Major Shareholder Announcement
4. Arpida Reports Interim Results for Six Months to 30 June 2008
5. Bavarian Nordic A/S - Interim Report for the Period 1 January to 30 June 2008
6. LPBP Inc. - Re-filing certification of interim filings
7. Fufeng Announces 2008 Interim Results With Strong Sign of Recovery
8. BioMS Medical announces positive interim analysis on phase III trial of dirucotide (MBP8298) for multiple sclerosis
9. Chromos obtains interim order in connection with arrangement, announces annual and special meeting of shareholders and confirms mailing of information circular
10. Quest PharmaTech Announces Interim Results from Phase I/II Clinical Trial for Photodynamic Treatment for Hair Removal
11. Angiotechs corporate partner, Cook Medical, announces positive interim results for its Zilver(R) PTX(TM) clinical study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... SAN FRANCISCO , Feb. 24, 2017 ... that is developing a new category of therapeutics, announced ... trial of SB-030 in peripheral artery disease. The trial ... locally administered single-use therapeutic, in the reduction of restenosis ... reached this critical development milestone for SB-030," said ...
(Date:2/24/2017)... China Cord Blood Corporation (NYSE: CO ) ... blood collection, laboratory testing, hematopoietic stem cell processing and ... results for the third quarter and first nine months ... Third Quarter of Fiscal 2017 Highlights ... increased by 18.6% to RMB200.9 million ($28.9 million). ...
(Date:2/24/2017)... -- China Biologic Products, Inc. (NASDAQ: CBPO) ("China Biologic" or ... China, today announced its financial results for the fourth quarter ... 2016 Financial Highlights Total sales in ... terms, or increased by 13.6% in USD terms to $77.6 ... Gross profit increased by 13.3% to $46.8 ...
(Date:2/24/2017)... , Feb. 24, 2017  OncoSec Medical Incorporated ("OncoSec") ... will host a Key Opinion Leader event to highlight ... oral and poster presentation at the upcoming 2017 ASCO-SITC ... KOL event will be held in-person and via live ... / 9:00 AM PST at the Lotte New York ...
Breaking Biology Technology:
(Date:1/24/2017)... 2017  It sounds simple and harmless—an electronic ... vital signs and alerts parents on their smart ... level drops. But pediatric experts argue that such ... no evidence of medical benefits, especially to healthy ... to parents of healthy babies, promising peace of ...
(Date:1/19/2017)... PORTLAND, Oregon and PUNE, India , January 19, ... Market Research, titled, "Global Biometric Sensor Market, Opportunities and Forecast, 2014 - ... 2022, growing at a CAGR of 9.6% from 2016 to 2022. In 2015, ... share owing to high-level security for both public and private sectors. ... ...
(Date:1/18/2017)... MINNETONKA, Minn. , Jan. 18, 2017 /PRNewswire/ ... eClinical technology company that supports the entire spectrum ... 2016 has been another record-breaking year for the ... and market interest in MedNet,s eClinical products and ... to the tremendous marketplace success of ...
Breaking Biology News(10 mins):